Quick Answer
Inhibitor Therapeutics, Inc. reported Cash and Equivalents of $2.38 million for fiscal year 2025.
Inhibitor Therapeutics, Inc. Cash and Equivalents — Annual History
| Fiscal Year | Cash and Equivalents | YoY Change |
|---|---|---|
| 2025 | $2.38M | -57.6% |
| 2024 | $5.61M | -36.6% |
| 2023 | $8.84M | -26.0% |
| 2022 | $11.95M | +38923.1% |
| 2021 | $30.6K | -59.2% |
| 2020 | $75.1K | -90.7% |
| 2019 | $803.8K | -27.5% |
| 2018 | $1.11M | +222.2% |
| 2017 | $344.1K | -95.0% |
| 2016 | $6.89M | +1044.8% |
| 2015 | $601.4K | +64.7% |
| 2014 | $365.2K | +168177.0% |
| 2013 | $217.00 | -100.0% |
| 2012 | $857.7K | -35.1% |
| 2011 | $1.32M | — |
Quarterly Cash and Equivalents
| Quarter Ending | Cash and Equivalents | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | $2.98M | -53.3% | -20.4% |
| June 30, 2025 | $3.74M | -47.3% | -13.5% |
| March 31, 2025 | $4.32M | -43.7% | -22.9% |
| December 31, 2024 | $5.61M | -36.6% | -12.1% |
| September 30, 2024 | $6.38M | -33.1% | -10.1% |
| June 30, 2024 | $7.10M | -29.7% | -7.6% |
| March 31, 2024 | $7.68M | -28.8% | -13.1% |
| December 31, 2023 | $8.84M | -26.0% | -7.3% |
- Inhibitor Therapeutics, Inc. showed a decrease of -57.6% in Cash and Equivalents compared to the prior fiscal year.
- Over the 2011–2025 period, Inhibitor Therapeutics, Inc.’s cash and equivalents has grown by 79.7% (from $1.32 million to $2.38 million).
- The most recent figure is from Inhibitor Therapeutics, Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 26, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: